Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Ligand Pharmaceuticals Incorporated - Common Stock
(NQ:
LGND
)
287.85
+6.13 (+2.18%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 26, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Ligand Pharmaceuticals Incorporated - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
Next >
Analyst Sees Big Upside In Ligand's Capital-Efficient Biotech Strategy
↗
April 10, 2025
Ligand earns Buy rating from Stifel for its royalty-based funding model and biotech partnerships amid strong revenue and earnings growth.
Via
Benzinga
This Ligand Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
↗
April 10, 2025
Via
Benzinga
Ligand to Report Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025
February 13, 2025
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Ligand to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
February 06, 2025
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Demystifying Ligand Pharmaceuticals: Insights From 10 Analyst Reviews
↗
December 11, 2024
Via
Benzinga
A Closer Look at 7 Analyst Recommendations For Ligand Pharmaceuticals
↗
November 08, 2024
Via
Benzinga
Assessing Ligand Pharmaceuticals: Insights From 7 Financial Analysts
↗
October 21, 2024
Via
Benzinga
Earnings Scheduled For May 8, 2025
↗
May 08, 2025
Via
Benzinga
Gold Falls Over 1%; D.R. Horton Posts Downbeat Earnings
↗
April 17, 2025
Via
Benzinga
Channel Therapeutics Stock Soars On Announcement Of Subsidiary’s Merger With Ligand Pharma Units: Retail’s Elated
↗
April 17, 2025
Under the agreement, Ligand’s wholly owned subsidiaries, Pelthos Therapeutics Inc. and LNHC, Inc. will combine with CHRO Merger Sub Inc., a wholly-owned subsidiary of Channel.
Via
Stocktwits
Dow Falls Over 1%; US Initial Jobless Claims Decline
↗
April 17, 2025
Via
Benzinga
Topics
Stocks
EXCLUSIVE: Ligand Subsidiary Pelthos Therapeutics To Combine with Channel Therapeutics Creating Pain Medicines Focused Entity
↗
April 17, 2025
Ligand and Channel Therapeutics to merge in $50 million deal to launch Zelsuvmi for molluscum and advance NaV 1.7 chronic pain programs.
Via
Benzinga
Earnings Scheduled For February 27, 2025
↗
February 27, 2025
Via
Benzinga
The Latest Analyst Ratings For Ligand Pharmaceuticals
↗
October 03, 2024
Via
Benzinga
Looking Into Ligand Pharmaceuticals's Recent Short Interest
↗
August 16, 2024
Via
Benzinga
Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts.
↗
January 09, 2025
Biotech stocks have seen three years of sideways to down trading. But obesity drugs, AI and Trump 2.0 promise to shake things up.
Via
Investor's Business Daily
Topics
Artificial Intelligence
Government
Ligand Hosts 2024 Investor and Analyst Day and Introduces 2025 Guidance
December 10, 2024
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Arcellx And Legend Bio Trade Jabs In Multiple Myeloma. But Only One Pulls Ahead.
↗
December 09, 2024
The companies held competing events on Sunday to discuss their multiple myeloma treatments.
Via
Investor's Business Daily
Ligand to Present at Stifel 2024 Healthcare Conference
November 14, 2024
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Ligand Reports Third Quarter 2024 Financial Results and Raises 2024 Guidance
November 07, 2024
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Ligand to Host Investor and Analyst Day on December 10, 2024 in Boston
November 01, 2024
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Ligand to Report Third Quarter 2024 Financial Results on November 7, 2024
October 23, 2024
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Critical Insights From Ligand Pharmaceuticals Analyst Ratings: What You Need To Know
↗
October 21, 2024
Via
Benzinga
Palvella Therapeutics Appoints Matthew E. Korenberg as Chief Financial Officer
October 17, 2024
Mr. Korenberg is a seasoned executive with significant operational and financial leadership experience, including senior roles at Ligand Pharmaceuticals (NASDAQ: LGND) and in healthcare investment...
From
Palvella Therapeutics
Via
GlobeNewswire
Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI® (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function Decline in IgA Nephropathy
September 06, 2024
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Ligand to Present at H.C. Wainwright 26th Annual Global Investment Conference
August 20, 2024
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Stock Market Rally Begins After Global Rout; Palantir, Eli Lilly, Fortinet Jump: Weekly Review
↗
August 09, 2024
After Monday's panicked global sell-off, markets have calmed down.
Via
Investor's Business Daily
LGND Stock Earnings: Ligand Pharmaceuticals Beats EPS, Beats Revenue for Q2 2024
↗
August 06, 2024
LGND stock results show that Ligand Pharmaceuticals beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
Via
InvestorPlace
Halozyme And Ligand — Two Leading Biotechs — Smash Quarterly Forecasts
↗
August 06, 2024
Halozyme and Ligand beat second-quarter expectations late Tuesday. But only one of the biotech stocks jumped.
Via
Investor's Business Daily
Ligand Reports Second Quarter 2024 Financial Results
August 06, 2024
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
